Unanticipated Problems Reporting Adverse Events to IRBs
FDA regulations governing adverse event reporting and IRBs have become outdated. At a time when clinical research is increasingly being conducted abroad and clinical trials are growing larger and more complex, IRBs are being inudated with single adverse event reports which they have neither the resources nor the expertise to analyze.
Global Growth Story Remains Strong for CROs in 2008
Contract research organizations (CROs) report strong growth across all phases of drug development as cancellation rates remain at historic lows. Public CRO shares remain a strong sector in a shaky stock market
Addressing the Shortage of Skilled Clinical Research in Europe
Difficulties finding and keeping suitable qualified clinical trials personnel have intensified in Europe. Observers agree that the available workforce simply isn't large enough to meet staffing needs.
Eye On: Prostate Cancer
Second only to skin cancer, prostate cancer is the most common cancer, according to the American Cancer Society.